HK1039932A1 - 使用馬杜拉二氮雜萘衍生物抑制前炎性細胞質變化 - Google Patents

使用馬杜拉二氮雜萘衍生物抑制前炎性細胞質變化

Info

Publication number
HK1039932A1
HK1039932A1 HK02101193.1A HK02101193A HK1039932A1 HK 1039932 A1 HK1039932 A1 HK 1039932A1 HK 02101193 A HK02101193 A HK 02101193A HK 1039932 A1 HK1039932 A1 HK 1039932A1
Authority
HK
Hong Kong
Prior art keywords
pro
inhibitors
maduraphthalazine
derivatives
inflammatory cytokins
Prior art date
Application number
HK02101193.1A
Other languages
English (en)
Inventor
Draheim Regina
Kronbach Thomas
Heinisch Lothar
Roemer Ernst
Hofgen Norbert
Poppe Hildegard
Jutten Peter
Haas Wolfgang
Werner Walter
Grafe Udo
Original Assignee
Dresden Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dresden Arzneimittel filed Critical Dresden Arzneimittel
Publication of HK1039932A1 publication Critical patent/HK1039932A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK02101193.1A 1999-04-17 2002-02-19 使用馬杜拉二氮雜萘衍生物抑制前炎性細胞質變化 HK1039932A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19917505A DE19917505A1 (de) 1999-04-17 1999-04-17 Verwendung von Maduraphthalazin-Derivaten als Inhibitoren proinflammatorischer Cytokine
PCT/EP2000/003182 WO2000063181A1 (de) 1999-04-17 2000-04-11 Verwendung von maduraphthalazin-derivaten als inhibitoren proinflammatorischer cytokine

Publications (1)

Publication Number Publication Date
HK1039932A1 true HK1039932A1 (zh) 2002-05-17

Family

ID=7904992

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02101193.1A HK1039932A1 (zh) 1999-04-17 2002-02-19 使用馬杜拉二氮雜萘衍生物抑制前炎性細胞質變化

Country Status (24)

Country Link
US (1) US6440968B1 (zh)
EP (1) EP1171425A1 (zh)
JP (1) JP2002542232A (zh)
KR (1) KR20010108515A (zh)
CN (1) CN1347408A (zh)
AU (1) AU4546100A (zh)
BG (1) BG106009A (zh)
BR (1) BR0009821A (zh)
CA (1) CA2305893A1 (zh)
CZ (1) CZ20013712A3 (zh)
DE (1) DE19917505A1 (zh)
EA (1) EA200101096A1 (zh)
EE (1) EE200100537A (zh)
HK (1) HK1039932A1 (zh)
HU (1) HUP0200783A3 (zh)
IL (1) IL145600A0 (zh)
IS (1) IS6093A (zh)
MX (1) MXPA01010050A (zh)
NO (1) NO20015033L (zh)
SK (1) SK14812001A3 (zh)
TR (1) TR200102984T2 (zh)
WO (1) WO2000063181A1 (zh)
YU (1) YU72601A (zh)
ZA (1) ZA200107886B (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210535D0 (en) * 2002-05-08 2002-06-19 Novartis Ag Organic compounds
WO2004011632A2 (en) * 2002-07-30 2004-02-05 Stem Cell Therapeutics Inc. Oligodendrocyte production from multipotent neural stem cells
WO2004056868A2 (en) * 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
WO2006042662A1 (de) * 2004-10-15 2006-04-27 Heidelberg Pharma Gmbh Parenterale darreichungsformen von imexon sowie verfahren zu deren herstellung
EP1908754B1 (en) * 2006-09-19 2009-01-28 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. Hans-Knöll-Institut Antibiotic maduraphthalazin salts with delayed release of the active substance and their use
KR102437853B1 (ko) 2016-07-11 2022-08-31 필립모리스 프로덕츠 에스.에이. 소수성 캡슐
WO2020126035A1 (en) * 2018-12-21 2020-06-25 Fondazione Istituto Insubrico Di Ricerca Per La Vita Novel aza-hexaphene antibiotic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE7706C (de) * Dr. G. H. E. BERING in Bromberg Verfahren zur Entbitterung von Lupinen mit Hülfe kohlensaurer Alkalien
DE19719522A1 (de) * 1996-08-17 1998-02-19 Gruenenthal Gmbh Neue polycyclische Phthalazinderivate, Verfahren zu Ihrer Herstellung und ihre Verwendung

Also Published As

Publication number Publication date
BG106009A (en) 2002-06-28
CN1347408A (zh) 2002-05-01
EE200100537A (et) 2002-12-16
JP2002542232A (ja) 2002-12-10
NO20015033D0 (no) 2001-10-16
HUP0200783A3 (en) 2002-12-28
HUP0200783A2 (hu) 2002-11-28
YU72601A (sh) 2004-05-12
SK14812001A3 (sk) 2002-05-09
DE19917505A1 (de) 2000-10-19
IL145600A0 (en) 2002-06-30
MXPA01010050A (es) 2002-04-24
EP1171425A1 (de) 2002-01-16
WO2000063181A1 (de) 2000-10-26
NO20015033L (no) 2001-11-21
BR0009821A (pt) 2002-01-15
EA200101096A1 (ru) 2002-04-25
ZA200107886B (en) 2004-03-29
IS6093A (is) 2001-09-28
KR20010108515A (ko) 2001-12-07
CZ20013712A3 (cs) 2002-03-13
CA2305893A1 (en) 2000-10-17
TR200102984T2 (tr) 2002-03-21
AU4546100A (en) 2000-11-02
US6440968B1 (en) 2002-08-27

Similar Documents

Publication Publication Date Title
AU3546601A (en) Pyrimidine-4-one derivatives as LDL-PLA<sub>2</sub> inhibitors
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
HUP0202450A3 (en) N-heterocyclic derivatives as nos inhibitors
AU4458700A (en) Uses of phenylglycine derivatives
GB9911417D0 (en) Furanone derivatives as inhibitors of cathepsin s
PL352296A1 (en) Crystalline derivatives of 1-methylocarbapeneme
HK1048302A1 (zh) 前列腺素衍生物
PL354979A1 (en) Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
AU3472600A (en) Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
PL355021A1 (en) Isoxazole derivatives to be used as phosphodiesterase vii inhibitors
AU2001292122A1 (en) Heterocyclic derivatives useful as pharmaceutical agents
IL145600A0 (en) Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins
PL355020A1 (en) Imidazole derivatives as phosphodiesterase vii inhibitors
AU1817700A (en) 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
IL149534A0 (en) Preparation of 3-substituted-4-arylquinolin-2-one derivatives
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
EP1157617B1 (en) Use of alpha-ketoenamine derivatives as cooling agents
GB0215275D0 (en) Benzo(a)phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II
EP1170286A4 (en) PROSTAGLANDIN E1 DERIVATIVES
AU4917000A (en) Oligohydroxyl substituted benzofuran-3-yl and pyridofuranylurea derivatives as phosphodiesterase iv inhibitors
AU4021700A (en) Methods of use of beta1-integrin inhibitors
HK1053059A1 (zh) 新用途
AU2002340038A1 (en) Method for the selective removal of acyl-functionality attached to the 2'-hydroxy-group of paclitaxel-related derivatives
AU6002700A (en) Heterocyclic derivatives as inhibitors of factor xa